Niagen Bioscience (NAGE) Cash from Financing Activities (2011 - 2026)

Niagen Bioscience (NAGE) has 14 years of Cash from Financing Activities data on file, last reported at -$2.3 million in Q1 2026.

• On a quarterly basis, Cash from Financing Activities fell 173.75% year-over-year to -$2.3 million in Q1 2026; TTM through Mar 2026 was $1.5 million, a 82.08% decrease from a year earlier, with the FY2025 full-year figure at $6.9 million, up 28.81% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at -$2.3 million, down from -$80000.0 in the prior quarter.
• Over the last five years, Cash from Financing Activities for NAGE reached as high as $7.7 million in Q4 2022 and fell as low as -$2.3 million in Q1 2026.
• Historically, Cash from Financing Activities has averaged $1.0 million across 5 years, with a median of -$3000.0 in 2022.
• On a YoY basis, Cash from Financing Activities climbed as much as 34733.33% in 2024 and fell as far as 1300.0% in 2024.
• Year by year, Cash from Financing Activities stood at $7.7 million in 2022, then slumped by 100.99% to -$76000.0 in 2023, then surged by 5031.58% to $3.7 million in 2024, then sank by 102.13% to -$80000.0 in 2025, then sank by 2762.5% to -$2.3 million in 2026.
• Per Business Quant data, the three most recent Cash from Financing Activities figures were -$2.3 million in Q1 2026, -$80000.0 in Q4 2025, and $148000.0 in Q3 2025.